The FDA has removed Risk Evaluation and Mitigation Strategies from several CAR T cell therapies, reducing regulatory requirements and facilitating broader use in clinical practice. Concurrently, the U.S. Centers for Medicare & Medicaid Services (CMS) established a reimbursement code for Eko Health’s AI platform designed to enhance early diagnosis of heart conditions. These regulatory and payment developments reflect growing acceptance of innovative therapies and AI tools to improve patient outcomes and access in cardiology.